No Data
Express News | Positive Results From Tezspire® (Tezepelumab-Ekko) Phase 3 Waypoint Trial Highlight Rapid, Sustained Effect in Chronic Rhinosinusitis With Nasal Polyps
Amgen Inc. (AMGN) Invests $200M in AI-Focused Tech Center in India, Plans to Hire 2,000 by 2025
Wall Street Today: Market Ends Wild Political TV Day in the Green
Unusual Options Activity: HAL, MRNA and Others Attract Market Bets, HAL V/OI Ratio Reaches 222.0
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
BEIGENE released its performance report for the year 2024, with total operating revenue of 27.214 billion yuan, a year-on-year increase of 56.2%.
BEIGENE (06160) released the performance report for the year 2024, with total revenue of 27.214 billion yuan (RMB, same below), an increase of 56.2% year-on-year; a net loss attributable to the parent company owner of 4.978 billion yuan, narrowing by 25.87% year-on-year; basic loss per share is 3.64 yuan. The announcement states that the increase in revenue is mainly due to the sales growth of Baiyueze (Zebutinib capsules), as well as Amgen authorized products and Baize'an (Tirabrutinib). In 2024, the global sales of Baiyueze totaled 18.859 billion yuan, a year-on-year increase of 106.4%, further in the field of hematologic oncology.
Unlock the Full List
HH1000 : but but this is lunr
Growth Investor27 HH1000 : $Esperion Therapeutics (ESPR.US)$ To the Moon. It has been sold hort & forced lower before an offer comes
HH1000 Growth Investor27 : i bought some calls for earnings a little while back. will see how that goes
72792912 : I no longer believe any positive rumors about this company
Rich2023 : Every day, some baseless rumors are spread.